18/03/2026 Idience's venadaparib received the FDA fast track designation for gastric cancer FluoGuide's FG001 imaging agent received the FDA fast track designation for glioma Idience's venadaparib received the FDA fast track designation for gastric cancer ( Ref ) The US FDA granted the fast track designation to Idience's venadaparib (PARP inhibitor) for the treatment of gastric cancer. Lee Won-sik, CEO, Idience: “ This Fast Track designation is highly meaningful in that the F